The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
[EN] COMPOUNDS FOR INHIBITING KIF18A<br/>[FR] COMPOSÉS POUR INHIBER KIF18A
申请人:[en]VOLASTRA THERAPEUTICS, INC.
公开号:WO2023212240A1
公开(公告)日:2023-11-02
The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer. (I)